Search

Your search keyword '"Wasieczko, A."' showing total 30 results
Start Over Author "Wasieczko, A."
30 results on '"Wasieczko, A."'

1. Computer assisted proof of Shil'nikov homoclinics: with application to the Lorenz-84 model

Author

Capinski, Maciej J. and Wasieczko-Zajac, Anna

Subjects
Mathematics - Dynamical Systems, 34C37, 37D05, 37D10, 65G20
Abstract

We present a methodology for computer assisted proofs of Shil'nikov homoclinic intersections. It is based on geometric bounds on the invariant manifolds using rate conditions, and on propagating the bounds by an interval arithmetic integrator. Our method ensures uniqueness of the parameter for which the homoclinic takes place. We apply the method for the Lorenz-84 atmospheric circulation model, obtaining a sharp bound for the parameter, and also for where the homoclinic intersection of the stable/unstable manifolds takes place., Comment: 22 pages, 6 figures

Published
2016

2. Geometric Proof of Strong Stable/Unstable Manifolds, with Application to the Restricted Three Body Problem

Author

Capiński, M. J. and Wasieczko, A.

Subjects
Mathematics - Dynamical Systems
Abstract

We present a method for establishing invariant manifolds for saddle--center fixed points. The method is based on cone conditions, suitably formulated to allow for application in computer assisted proofs, and does not require rigorous integration of the vector field in order to prove the existence of the invariant manifolds. We apply our method to the restricted three body problem and show that for a given choice of the mass parameter, there exists a homoclinic orbit to one of the libration points., Comment: 34 pages, 6 figures

Published
2014

8. Abstracts of posters

Author

Suffisseau L., Taugourdeau M. C., Goldstein F. W., Mainardi J. L., Larrouturou Ph., Romero, M., Cervino, A. R., Albertone, G., Di Pasquale, R., Venturini, F., Congedo, R., Benettolo, F., Pistolesi, C., Olivato, R., Casasin T., Agusti C., Gurrera M. T., Fabregas X., Rizo A., Badia J. M., Santa-Olalla M., Marini, P., Rampazzo, R., Scroccaro, G., Dell'Aera, M., Luzzi, R., Ciccarone, G., Martinet, N., Beney, J., Marty, S., Reymond, J. -Ph., Cairns, Chris, Morgutti M., Posco M., Moltempi M., Lonqhini P., Rossignoli A., Rihet, P., Carles, G., Braguer, D., Azulay, J. P., Pouget, J., Pelletier, J., Crevat, A., Past.o, L., Barroso, E., Pujol, R., Ferrer, I., Ibars, M., Llop, J. M., Frankfort, Ellen, van Dongen, Robert T. M., Hekster, Yechiel A., Kart, T., Rasmussen, M., Horn, A., Wested, L., Gagyi, O., Markó, E., Regazzi M. B., Martinelli L., Goggi C., Bellotti E., Molinaro M., Rinaldi M., Gavazzi A., Buggia I., Daneri A., Guarnone E., Bascapē V., Viganô M., Lazzaro, A., Palozzo, A., Banfi R., Borselli G., Fabbiani P., Marinai C., Delorme, J., Tubiana, N., Buck, M., Chinot, O., De Wever, C., Robays, H., Montoro J. B., Flores G., Juárez J. C., Juste C., Jardí R., Altisent C., Tusell J. M., Arpinelli, F., De Carli, G., Olivieri, A., Recchia, G., Rossignoli A., Longhini P., La Guidara C., Russo B., Moltempi M., Tamés, M. J., Cajaraville, G., Ponz, L., Echaniz, E., Garcia, B., van Mil, J. W. Foppe, Leufkens, Hubert G., v. Haelst, Ingrid M. M., Parel, Piet C. M., Scholten, Wim K., Sessink, F. G. M., Raschatt, R., Traversa, G., Donini, G., Arpino, C., Da Cas, R., Pasquin, P., Bernadotte af Wisborg G., Claesson C., Lundberg O., Thorslund M., Ferraro L., Marrazzo E., Ostino G., Tognoni G., Heerdink, Eibert R., Koppedraaijer, Corrie, Bakker, Albert, Bidoli E., Battistin M., Troncon M. G., Franceschi S., Serraino D., Marino, M., Matera, M. G., Berrino, L., Contaldi, C., Piucci, B., Rossi, F., Rolle C., Marrazzo E. 0., Murgia, V., Bussi, R., Schievano, P., Pedrini, A., Baraghini, M., Benini, A., Cataldo, M. M., Galletti, P., Magnani, M., Manzoli, M., Novi, M. V., Pezzi, O., Font M., Salmaso A. B., Mezzalira L., Braybrook, Saran, Walker, Roger, van Mil, J. W. F., Tromp, F. T. J., de Jong-v.d. Berg, L. T. W., Bakker, A., Paes, A. H. P., Soe-Agnie, C., Llopis, P., Tortajada, J. J., Font, I., Climente, M., Real, J. V., Almenar, D., Molins, C., Jiménez, N. V., Bellés Medall MD, Casterá Melchor DE, Marco Sena MA, Cantarinz Marti I., Abad Gimeno FJ, Török, J., Thurzó, L., Juárez J. C., Oliveras M., Hidalgo E., Cabañas M. J., Barroso C., Moraga F. A., Sánchez de Toledo J., Kollöffel, W. J., Driessen, F. G. W. H. M., Goldhoorn, P. B., Moral, M. A., Roglan, A., Mangues, M. A., Bonal, J., Clopés, A., Badell, I., Fraga, G., Deinum, J. T., van Lingen, R. A., Quak, J. M. E., Kuizenga, A. J., van Dam, J. G., Villani P., Maserati R., Viale P., Alberici F., Iacona I., Wasieczko, A., Szymura-Oleksiak, J., Wyska, E., Magulova, L., Sirotiakova, J., Letkovicova, M., Branger, E., Besse, D., Blin, O., Bille, F., Serratrice, G., Desnuelle, C., Grassin, J., Reben, I., Meunier, Ph., Antier, D., Berthet, M., Søndergaard B., Herborg H., Frøkjær B., Hepler C., Steckner, H., Bergold, A., Drings, P., Märkel, A., Manegold, C., Venning, Mary, Pazzagli, Luciana, Semmola, Maria Vittoria, Mannoni, Alessandro, Tersen I., Huchet J., Sevilla, E., Ferrari, J. M., Herreros de Tejada, A., Congedo, R., Font, M., Fraccaro, A., Osti, M., Pappagallo, G., Spolaor, A., Terrazzani, G., Vezzani, M., Edouard B., Laine G., Geeraerts D., Robays H., Carrera-Hueso, F. J., Font, B., Marquina, C., Idoate, A., Giráldez, J., Fernández, E., Lacasa, C., Guzzo, D., Martini, N., Boya, P. Giner, González, M. M. Negredo, Agulló, J. Muñoz, Mansilla, L. Lorente, Nahata, Milap C., Troncon, M. G., Cattaruzzi, C., Bilbao G., Galende I., Atañé C., Bermudez de Castro A., Delgado O., Escribano B., Frías J., Gabriel R., Gómez J. A., Gracia D., Gutiérrez E., Hellín T., Izquierdo J. L., Moreno A., Requena T., Sainz-Terreros M., Tejedor J. C., Torralba A., Vigil D., Scuffi, C., Trallori, G., Messori, A., Bardazzi, G., Bonanomi, A., Silvano, R., D'Albasio, G., Bardelli, F., Verona, Firenzee, Bardelli, F., Corrado, A., Ferriols R., Aleixander M. J., Garcia J., Faus M., Ibañez E., Alós M., Rinaldi, M., Pharmacy & Therapeutic Committee (Ps&TC), Collaborative Group, SIFO-Veneto Working Group on Clinical Trials, Working Group on the Elaboration of an Approval Conditions Document to certify the Clinical Trials Ethics Committees in the Autonomous Community of Madrid, and Area SIFO di Metanalisi

Published
1994
Full Text
View/download PDF

9. Abstracts of papers and posters safe handling of medicines

Author

Meyer, H. -J., Tromp, Th(Dick) F. J., van der Kleijn, E., Fields, Suzanne M., Moors, J. P. P., Enlund, H., Luscombe, D. K., Remond, J -Ph, Martv, S., Dhillon, S., Taylor, D., Kostrzewski, A., Bluml, B. M., Enlow, M. L., Metzler, S. E., de Vries, Philip A., Duty, C. J., Lee, H. Y., Ábrahám, Tibor, Cardoni, A. A., Sýkora, J., Szücsová, S., Reymond, J. -Ph, Marty, S, Engová, D., Sheridan, J., Vlček, J., Webb, D. G., Bates, I. P., Tabachnik A., Cass Y., Jacobs J., Vexler A., Gorodetsky, R., Whittlesea, C. M. C., Walker, R., Khan, F., Houghton, J., Phillips, I., Szymura-Oleksiak, J., Wasieczko, A., Wyska, E., Ayani, I., Errecalde, M. F., Rodriauez-Sasiain, J. M., Aouirre, C., Bellés Medall M. D., Casabó Alos V. G., Hervás Botella M. A., Cabrera Pérez A., Jiménez Torres N. V., Casterá Melchor D. E., Abad Gimeno F. J., Clark, J. E., Gomez, E. C., Cruz, A. C., Wilbur, R. L., Alfonso, I., Grout, C. H., Goldstein, R., Rivers, P., Stutz, K., Mühlcbach, S., Udeani, George, Zervopoulous, Irene, Patel, Krishna, Mullane, Michael, Radziwill, R., Dudek, J., Herbst, U., Bency, J., Muff, P., Marty, S., Rcymond, J. -Ph, Aumente M. D., Panadero M. D., Latre J. M., Torres M., Villegas M. J., Alvarez J., van Dijk, E. A., Logman, E. M., Ploeger, B., van der Schors, T. G., Steensma, D. J., Langlois-Karaga, A., Davignon, A., Bues-Charbit, M., Somme, V., Albanese, J., Durbec, O., Martin, C., Morati, N., Balansard, G., Pereira, M. E. Araújo, Nogueira, A., Silva, J. C., Mega, I., Costa, A. Gomes, Morais, J. A., Prata, M. M., Cajaraville, G., Tamés, M. J., García, B., Batel Marqucs F. J., Capela H. S., Pomingues P., Feio J. A., Siha C., Wolter, K., Fritschka, E., Schneesann, H., Stuurman, A., Gudjonsdottir, A., Angelo, H. R., Rasmuassen, M., Rasmussen, S. N., Carrera, J., Idoate, A., Modrego, A., Tejedor, I., Giráldez, J., Mangues, M. A., Farré, R., Demestre, X., Ginovart, G., Orozco, J., Julio, G., Moral, M. A., Busin, C., Bardin, C., Seroux, C., Sauvageon-Martre, H., Sraer, J. -D., Chast, F., Real, J. V., Climente, M., Font, I., Pérez, C., Ordovás, J. P., Hermenegildo, M., Catalán, J. L., Juan, J., Jiménez, N. V., Amiot, F., Clavel, S., Sarrut, B., Doreau, C., Hips, F. Zs, Soós, Gy, Petô-Nagy, G., Vincze, Z., Robays H., Freidank, A., Fischer, A., Cordovilla, H., Font, B., Ortega, A., Salek, M. S., Thomas, S., Baver, A. J., Vandenbroucke J., Ekedahl, A., Tuovinen K., Wallenius K., Enlund H., Boeke, A. W., Veenstra, E. J., van de Poll, M. A. P. C., Nonkes, K., Carlen, I., Tanner, M., Reinke, C., Escher, J., Fischer, J., Marly, S., Ooi, G. K., Cottle, A., Savage, A., Temesvári, E., Montero, M. C., Pastor, M., Valdivia, M. L., Buenestado, C., Lluch, A., Atienza, M., Santos, B., Echeverria Roca M., Fernandez Gallastegui S., Alonso Rizaldos C., Arce Trueba M. D., Booth, C. D., Aldaz, A., Lacasa, C., Cordovilla, M., Alzina, V., Sheridan, J. L., Webb, D. G., Usselmann, B., Carstens, G., Falcao, A. C., Femández de Gatta, M. M., Cobo, F. Nieto, Gorzátez, A. C. Alonso, Lanao, J. M., Dominguez -Gil, A., Burr, A., Ferreira, M. P., Rodrigues, M. O., Pereira, M. E., Marques, M. F., Vicente, M. C., Carrondo, A. P., Pires, M. A., Granja, M. A., Tuneu L., Serna J., Saló E., Cerutti P., Cardona P., Bonal J., Cosh, D. G., Abbott, F., Alderman, C. P., Mav, F. W., Peters, P. G., Scott, S. D., Jenkins, D., Cairns, C., Barber, N. D., Cammie, S. M., Burr, A. J., Brännström, I., Boya, P. Giner, Aliaga, C. Parreño, González, M. M. Negredo, Mansilla, L. Lorente, Pidrman, V., Fendrich, Z., Alberola, C., Castillo, B., Girón, C., Morell, A., López-Calull C., Carcia-Capdevila L., Sanz M., Cardona D., Castro I., Farré R., Saura R., Pérez J. M., Johnsen, Eva, Krogsgård, Ole, Pinheiro, R. L., Morais, I. A., Batel Marques F. J., Domingues P., Feio J. A., Silva C., Astdrager, C. L. L., Schnlekamp, T., de Gier, J. J., Rutten, C. W. H., Rivera, M. C., Vilanova, M., Mattei, I., Roglan, A., Serna, J., and Bonal, J.

Published
1993
Full Text
View/download PDF

10. Geometric proof of strong stable/unstable manifolds with application to the restricted three body problem

Author

Maciej J. Capiński and Anna Wasieczko-Zając

Subjects
Pure mathematics, Cone (topology), Matching (graph theory), Applied Mathematics, Ode, Lagrangian point, Vector field, Homoclinic orbit, Fixed point, 16. Peace & justice, Three-body problem, Analysis, Mathematics
Abstract

We present a method for establishing strong stable/unstable manifolds of fixed points for maps and ODEs. The method is based on cone conditions, suitably formulated to allow for application in computer assisted proofs. In the case of ODEs, assumptions follow from estimates on the vector field, and it is not necessary to integrate the system. We apply our method to the restricted three body problem and show that for a given choice of the mass parameter, there exists a homoclinic orbit along matching strong stable/unstable manifolds of one of the libration points.

Published
2015

14. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression

Author

Joanna Szymura-Oleksiak, Elżbieta Wyska, and Andrzej Wasieczko

Subjects
Male, Imipramine, Metabolite, Ultrafiltration, Pharmacology, Antidepressive Agents, Tricyclic, chemistry.chemical_compound, Pharmacokinetics, Antimanic Agents, Desipramine, Blood plasma, medicine, Humans, Drug Interactions, Biotransformation, Depressive Disorder, business.industry, Carbamazepine, Drug interaction, Middle Aged, chemistry, Free fraction, Female, business, medicine.drug, Protein Binding
Abstract

Rationale: Despite the fact that carbamazepine (CBZ) is frequently added to the existing tricyclic antidepressant (TCA) therapy, to date little is known about serum levels of pharmacologically active hydroxy metabolites of TCAs, as well as about possible changes in free (non-protein-bound) concentrations of these drugs and their metabolites during such combination treatment of depression. Objective: The aim of this study was to evaluate the effect of CBZ on steady-state total and free serum concentrations of imipramine (IMI) and its metabolites, desipramine (DMI), 2-hydroxyimipramine and 2-hydroxydesipramine, in depressed patients. In addition, the free and total serum concentrations of CBZ and 10,11-epoxycarbamazepine were measured. Method: Thirteen patients with DSM-III-R diagnosis of major depression were enrolled in the study. All patients hospitalised at the Department of Psychiatry, Collegium Medicum, Jagiellonian University were treated with IMI at a dose of 2 mg/kg per day for 3 weeks, after which CBZ at a dose of 400 mg/day was added. Steady-state serum concentrations of IMI, CBZ and their metabolites were assayed by HPLC. Free drug concentrations were measured by ultrafiltration. Results: After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84±102.18 to 98.12±43.79 ng/ml) and DMI (from 293.89±171.93 to 221.85±153.21 ng/ml) was observed. Simultaneously, steady-state serum concentrations of total hydroxy metabolites and free IMI and its metabolites, measured just before and 2 weeks after CBZ were started, did not differ significantly. In consequence, a significant increase in free fraction of the parent drug was observed (3.36±3.24% vs 5.75±3.60%). Also free fraction of DMI tended to be higher after CBZ addition. Conclusion: CBZ affects not only the metabolism of IMI and its metabolites, but also their protein binding. Therefore, despite considerable reductions in total serum levels of IMI and DMI, but when the unchanged free fraction concentration of these compounds is maintained, a dosage elevation of IMI does not seem to be necessary after CBZ addition to TCA therapy.

Published
2001

16. [Clinical pharmacokinetics of tricyclic antidepressants Part II. Drug therapy monitoring]

Author

J, Szymura-Oleksiak, A, Wasieczko, E, Wyska, and A, Zieba

Subjects
Depressive Disorder, Electrocardiography, Dose-Response Relationship, Drug, Humans, Antidepressive Agents, Tricyclic, Drug Monitoring
Abstract

Large interindividual variation in steady-state TCA plasma concentrations, the presence of active metabolites, narrow therapeutic range and life-threatening results of TCA overdosage constitute indications for therapeutic drug monitoring. Conditions which must be fulfilled in order that serum concentration measurements may be taken into consideration in routine practice were discussed. The most important ones are: relationship between TCA concentration and antidepressant effect, the knowledge of therapeutic TCA range and availability of rapid and sensitive analytical method. Pharmacokinetic methods of TCA dosage individualization were also described. TCA serum concentration monitoring and dosage individualization of these drugs allows the clinician to optimize treatment of depression.

Published
1994

17. [Clinical pharmacokinetics of tricyclic antidepressants. Part I. Pharmacokinetic properties]

Author

J, Szymura-Oleksiak, A, Wasieczko, E, Wyska, and A, Zieba

Subjects
Male, Depressive Disorder, Plasma, Dose-Response Relationship, Drug, Humans, Female, Antidepressive Agents, Tricyclic
Abstract

Pharmacokinetic properties of tricyclic antidepressants (TCA) and factors changing pharmacokinetics of these drugs were presented. The following factors were discussed: age, genetically determined rate of metabolism and TCA interaction with co-administered drugs. As a consequence of these factors alterations mainly in elimination of TCA are observed. It leads to large interindividual variation in TCA plasma concentrations and lack of correlation between TCA concentration and dosage.

Published
1993

18. [Clinical usefulness of monitoring serum levels of imipramine and desipramine in patients treated for endogenous depression]

Author

J, Szymura-Oleksiak and A, Wasieczko

Subjects
Adult, Male, Depressive Disorder, Imipramine, Dose-Response Relationship, Drug, Desipramine, Humans, Female, Drug Monitoring, Middle Aged
Abstract

Fifteen patients with endogenous unipolar and bipolar depression were treated with imipramine and, if necessary, one of benzodiazepine or neuroleptic. Total serum concentrations of imipramine (IMI) and its active metabolite desipramine (DMI) were measured in steady-state by FPIA method . Severity of depression was assessed using the Hamilton Depression Rating Scale. IMI + DMI serum concentration monitoring appeared to be useful in every case. It helped to arrive more quickly at the optimal dosage, confirmed the suspicion of overdosage or noncompliance. In nonresponders group, it helped with the earlier decision of changing brands of tricyclic antidepressant or it contributed to intensify the diagnostic process which detected the additional pathology.

Published
1991

24. [Sulpiride: an atypical neuroleptic with a wide spectrum of therapeutic claims].

Author

Wasieczko A and Wasieczko Z

Subjects
Antipsychotic Agents adverse effects, Antipsychotic Agents pharmacokinetics, Antipsychotic Agents therapeutic use, Humans, Mood Disorders drug therapy, Schizophrenia drug therapy, Somatoform Disorders drug therapy, Sulpiride adverse effects, Sulpiride pharmacokinetics, Sulpiride therapeutic use
Published
1996

25. [Preliminary results of the study on the combined treatment of endogenous depression].

Author

Zieba A, Wasieczko A, Jawor M, Dubiel D, and Kubiak J

Subjects
Adult, Cognitive Behavioral Therapy, Combined Modality Therapy, Depressive Disorder diagnosis, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Carbamazepine therapeutic use, Depressive Disorder drug therapy, Depressive Disorder therapy, Lithium therapeutic use
Published
1995

26. [Clinical pharmacokinetics of tricyclic antidepressants Part II. Drug therapy monitoring].

Author

Szymura-Oleksiak J, Wasieczko A, Wyska E, and Zieba A

Subjects
Antidepressive Agents, Tricyclic administration & dosage, Antidepressive Agents, Tricyclic therapeutic use, Depressive Disorder metabolism, Dose-Response Relationship, Drug, Electrocardiography drug effects, Humans, Antidepressive Agents, Tricyclic pharmacokinetics, Depressive Disorder drug therapy, Drug Monitoring
Abstract

Large interindividual variation in steady-state TCA plasma concentrations, the presence of active metabolites, narrow therapeutic range and life-threatening results of TCA overdosage constitute indications for therapeutic drug monitoring. Conditions which must be fulfilled in order that serum concentration measurements may be taken into consideration in routine practice were discussed. The most important ones are: relationship between TCA concentration and antidepressant effect, the knowledge of therapeutic TCA range and availability of rapid and sensitive analytical method. Pharmacokinetic methods of TCA dosage individualization were also described. TCA serum concentration monitoring and dosage individualization of these drugs allows the clinician to optimize treatment of depression.

Published
1994

27. [Clinical pharmacokinetics of tricyclic antidepressants. Part I. Pharmacokinetic properties].

Author

Szymura-Oleksiak J, Wasieczko A, Wyska E, and Zieba A

Subjects
Antidepressive Agents, Tricyclic blood, Antidepressive Agents, Tricyclic therapeutic use, Depressive Disorder drug therapy, Dose-Response Relationship, Drug, Female, Humans, Male, Plasma metabolism, Antidepressive Agents, Tricyclic pharmacokinetics, Depressive Disorder metabolism
Abstract

Pharmacokinetic properties of tricyclic antidepressants (TCA) and factors changing pharmacokinetics of these drugs were presented. The following factors were discussed: age, genetically determined rate of metabolism and TCA interaction with co-administered drugs. As a consequence of these factors alterations mainly in elimination of TCA are observed. It leads to large interindividual variation in TCA plasma concentrations and lack of correlation between TCA concentration and dosage.

Published
1993

28. [Clinical usefulness of monitoring serum levels of imipramine and desipramine in patients treated for endogenous depression].

Author

Szymura-Oleksiak J and Wasieczko A

Subjects
Adult, Depressive Disorder metabolism, Desipramine blood, Desipramine pharmacokinetics, Dose-Response Relationship, Drug, Drug Monitoring, Female, Humans, Imipramine blood, Imipramine pharmacokinetics, Male, Middle Aged, Depressive Disorder drug therapy, Desipramine administration & dosage, Imipramine administration & dosage
Abstract

Fifteen patients with endogenous unipolar and bipolar depression were treated with imipramine and, if necessary, one of benzodiazepine or neuroleptic. Total serum concentrations of imipramine (IMI) and its active metabolite desipramine (DMI) were measured in steady-state by FPIA method . Severity of depression was assessed using the Hamilton Depression Rating Scale. IMI + DMI serum concentration monitoring appeared to be useful in every case. It helped to arrive more quickly at the optimal dosage, confirmed the suspicion of overdosage or noncompliance. In nonresponders group, it helped with the earlier decision of changing brands of tricyclic antidepressant or it contributed to intensify the diagnostic process which detected the additional pathology.

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results